Oxygen Biotherapeutics Provides Update On Recent Events And Phase IIb Oxycyte Clinical Trial

Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) is providing an update on the status of the Oxycyte® Phase IIb protocol that has been submitted to the FDA. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. “We are in the process of submitting a final piece of information requested by the FDA. After that data has been submitted, we will wait to hear back from them.

More: continued here

Filed under: Clinical Trials on July 16th, 2008